Why is CME Group delisting from the NYSE?

The 8-K filing states CME Group's intention to list its Class A common stock solely on NASDAQ OMX. While not explicitly stating a reason, this typically suggests a strategic decision to simplify operations, reduce dual listing costs, and potentially concentrate trading volume and analyst coverage on one exchange.

What is the significance of the amended license agreement with NASDAQ OMX?

The amendment extends the exclusive license term with NASDAQ OMX until December 31, 2019. This ensures continued access to services provided by NASDAQ OMX, for which CME Group pays per-trade fees. Investors should note the long-term nature of this agreement and the ongoing operational costs associated with it.

How will this affect the trading of CME Group's stock?

By consolidating its listing to NASDAQ OMX, CME Group's stock will no longer be traded on the NYSE. This could lead to a change in trading volume, market maker participation, and potentially the visibility of the stock. Investors will need to access and trade CME Group shares exclusively through NASDAQ OMX.

Are there any financial implications of the license agreement extension?

The filing mentions that CME Group pays per-trade fees to NASDAQ OMX under the license agreement. The extension to 2019 implies these fees will continue. Investors should consider these ongoing operational expenses as part of CME Group's cost structure.

CME 8-K: Material Agreements & Securities & Listing

Summary

CME Group Inc. (CME) filed an 8-K on June 30, 2008, detailing two significant strategic decisions. The company amended its existing license agreement with NASDAQ OMX, extending the exclusive license term for certain services until December 31, 2019. This extension involves continued per-trade fee payments to NASDAQ OMX. More importantly for investors, CME announced its intention to delist its Class A common stock from the New York Stock Exchange (NYSE) and maintain a sole listing on the NASDAQ OMX. This move, effective June 30, 2008, signifies a consolidation of CME's trading presence and a simplification of its listing structure, potentially impacting liquidity and investor access on a single exchange.

Key Highlights

1CME Group amended its license agreement with NASDAQ OMX, extending the exclusive license term to December 31, 2019.
2The amendment involves continued per-trade fee payments to NASDAQ OMX.
3CME Group intends to delist its Class A common stock from the New York Stock Exchange (NYSE).
4The company will maintain a sole listing for its Class A common stock on NASDAQ OMX.
5This delisting decision was formally communicated to the NYSE on June 30, 2008.
6The filing indicates a strategic move towards concentrating trading on a single exchange.

CME GROUP INC. 8-K Report, Material Agreement (Jun 30, 2008)

Summary

Key Highlights

Frequently Asked Questions